Jazinaki · Phytotherapy research : PTR 2024 · systematic review and meta-analysis of randomized controlled trials · n=11 studies (696 participants)

The effect of pomegranate juice supplementation on C-reactive protein levels: GRADE-assessed systematic review and dose-response updated meta-analysis of data from randomized controlled trials.

Cited 3 times in the scientific literature.

Level 1 - systematic review of randomized trials

Systematic review and meta-analysis of randomized controlled trials

PubMed 38553998 · doi:10.1002/ptr.8188 · record verified 2026-08-28

What was done

A systematic review and meta-analysis of randomized controlled trials (RCTs) searched PubMed, Scopus, and Web of Science through July 2023 to evaluate the effect of pomegranate juice (PJ) supplementation on C-reactive protein (CRP) levels. Risk of bias was assessed, and pooled effect sizes were calculated using random-effects models as weighted mean differences (WMD) with 95% confidence intervals (CI). Linear and nonlinear dose-response meta-regressions were also conducted across 11 included studies (13 effect sizes, 696 participants).

What was found

PJ supplementation significantly reduced CRP levels compared to control groups (WMD: -2.55 mg/L; 95% CI: -3.44 to -1.66; p < 0.001). Significant reductions were observed in subgroups of both sexes or females only, Iranian populations, individuals aged 40 years and older, participants with type 2 diabetes or polycystic ovary syndrome, and trials using dosages < 250 mL/day. Dose-response and meta-regression analyses found no significant linear or nonlinear relationship between PJ dose or duration and CRP changes.

Why it matters

This updated meta-analysis suggests that pomegranate juice can reduce circulating CRP, providing quantitative evidence of an anti-inflammatory effect where earlier meta-analyses had reported nonsignificant findings.

Limits

The total sample size across all 11 studies was modest (696 participants). The absence of a significant dose-response relationship obscures optimal dosing and intervention duration. Significant subgroup results were clustered in specific demographics (e.g., Iranian cohorts, specific metabolic conditions), limiting generalizability to broader healthy or diverse populations.

Cited by